Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

“…Since infusion reactions occurred in 4/9 (44.4%) of the Isa-Pd group in the Japanese cohort of the ADR adverse drug reaction a Each participant could have experienced more than one ADR, serious ADR and/or ADR event of each severity grade b All ADRs were of Grade 3-4; no Grade 5 ADRs were reported c Localized reactions associated with the infusion procedure Because data capture was performed under routine medical care, it is reasonable to assume that only serious ADRs requiring infusion reaction supportive care were retrieved from medical records, and that mild infusion reactions were not recorded and underestimated in our study. However, the incidence of infections in this PMS was lower than that reported in a retrospective study of individuals (n = 107) treated with Isa-Pd in routine care in 24 centers in the UK (23.4%) [19]. Cardiac disorders were very uncommon in the current PMS, reported in only one participant (< 1%).…”

COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

“…Some studies reported high frequencies of severe COVID-19 in MM patients under anti-CD38 treatments. 13 , 14 Its mechanism of action can explain the association with the severity of COVID in our cohort.…”

“…5 Studies in other cancer patients' subgroups also reported modifications in the patient's care during COVID. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 …”

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients

“…We found an independent association between a high co-morbidity burden (CCI ≥4) and the incidence of ≥G3 infections, and a protective effect of an objective myeloma response (≥PR) from ≥G3 infections. 13 In order to reduce the incidence of infections, particularly in frail patients and those with co-morbidities, we recommend close monitoring, and the optimal use of anti-infective prophylaxis strategies. Anti-infective prophylaxis should include the preventative use of antivirals in addition to antifungals and pneumocystis pneumonia (PCP) prophylaxis.…”